Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Quiz|Articles|March 27, 2026
OncLive Weekly News Quiz (3/27/2026): Test Your Knowledge on Ovarian, Lung Cancer Updates and More
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The phase 3 ROSELLA trial (NCT05257408) supporting the FDA approval of relacorilant (Lifyorli) plus nab-paclitaxel (Abraxane) demonstrated which of the following key outcomes compared with nab-paclitaxel alone in patients with platinum-resistant ovarian cancer?
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5